Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - SARS-CoV-2 and cancer 1

LBA77 - Anti-SARS-CoV-2 antibody response in patients with cancer and oncology healthcare workers: A multicenter, prospective study


18 Sep 2020


Mini Oral - SARS-CoV-2 and cancer 1


COVID-19 and Cancer

Tumour Site


Antonio Marra


Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325


A. Marra1, D.G. Generali2, P. Zagami1, S. Gandini3, V. Cervoni2, S. Venturini4, S. Morganti1, R. Passerini5, R. Orecchia6, G. Curigliano1

Author affiliations

  • 1 Divisione Sviluppo Di Nuovi Farmaci Per Terapie Innovative, Istituto Europeo di Oncologia IRCCS, Università di Milano, 20141 - Milan/IT
  • 2 Uo Patologia Mammaria E Ricerca Traslazionale - Breast Unit, Azienda Socio-Sanitaria Territoriale di Cremona and University of Trieste, 26100 - Cremona/IT
  • 3 Experimental Oncology, Istituto Europeo di Oncologia IRCCS, 20141 - Milan/IT
  • 4 Dipartimento Di Management, Università di Torino, 10134 - Torino/IT
  • 5 Division Of Laboratory Medicine, Istituto Europeo di Oncologia IRCCS, 20141 - Milan/IT
  • 6 Scientific Direction, Istituto Europeo di Oncologia IRCCS, 20141 - Milan/IT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract LBA77


Poor outcomes for patients with cancer and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease (COVID-19) have been reported so far. Although anti-SARS-CoV-2 IgG response is usually detectable within three weeks after infection, limited information on the seroconversion rate of patients with cancer infected by SARS-CoV-2 is available.


This is a multicenter, observational, prospective study that included patients and oncology healthcare workers (HCWs) with SARS-CoV-2 infection confirmed by RT-PCR or clinical/radiological suspicious of infection as well as patients with cancer who are considered at high risk for infection. All subjects were tested with the 2019-nCoV IgG/IgM Rapid Test Cassett for the fast detection of IgG and IgM antibodies against SARS-CoV-2. The aim of the study was to evaluate anti-SARS-CoV-2 seroconversion rates by qualitative assay in patients with cancer and HCWs with confirmed or clinically suspected COVID-19.


At first interim analysis, 166 subjects were enrolled in the study. Cancer patients and HCWs were 61 (36.7%) and 105 (63.3%), respectively. HCWs were younger than patients with cancer (median age 41 vs 62 years; P<0.001). Eighty-six subjects (51.8%) had confirmed SARS-CoV-2 diagnosis by RT-PCR testing on nasopharyngeal swab specimen, while forty-nine (29.5%) had a clinical suspicious of COVID-19 in absence of RT-PCR confirmation. In patients with RT-PCR-confirmed SARS-CoV-2 infection, 62 (83.8%) were IgG-positive. Neither differences in terms of IgG positivity (87.9% vs 80.5%; P=0.39) nor in median time from COVID-19 diagnosis to IgG detection (23.0 vs 28.0 days; P=0.21) were found between patients with cancer and HCWs.


Our data show that SARS-CoV-2-specific IgG antibody response is not different between cancer patients and healthy subjects. Qualitative rapid test for antibody detection represents an useful support to RNA RT-PCR testing for the diagnosis of COVID-19 in high-risk populations, including patients with cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Istituto Europeo di Oncologia IRCCS.


This work was partially supported by the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds. MEDnoTE srl (Spin-off of University of Trieste) supported the present study by providing the rapid test used for anti-SARS-CoV-2 antibody detection.


D.G. Generali: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Novartis, Pfizer, Lilly. G. Curigliano: Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy: Mylan, Daichii Sankyo; Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly, Pfizer, Merck, Foundation Medicine, Samsung, Celltrion; Advisory/Consultancy, Speaker Bureau/Expert testimony: Seattle Genetics, Nanostring; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Speaker Bureau/Expert testimony: Novartis, BMS; Honoraria (self): Ellipsis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.